Lentiviral Vectors for Ocular Gene Therapy
Open accessThe DOI matches its Crossref record; 206 of the 208 references it cites were found in a registry or an index.
Abstract
This review offers the basics of lentiviral vector technologies, their advantages and pitfalls, and an overview of their use in the field of ophthalmology. First, the description of the global challenges encountered to develop safe and efficient lentiviral recombinant vectors for clinical application is provided. The risks and the measures taken to minimize secondary effects as well as new strategies using these vectors are also discussed. This review then focuses on lentiviral vectors specifically designed for ocular therapy and goes over preclinical and clinical studies describing their safety and efficacy. A therapeutic approach using lentiviral vector-mediated gene therapy is currently being developed for many ocular diseases, e.g., aged-related macular degeneration, retinopathy of prematurity, inherited retinal dystrophies (Leber congenital amaurosis type 2, Stargardt disease, Usher syndrome), glaucoma, and corneal fibrosis or engraftment rejection. In summary, this review shows how lentiviral vectors offer an interesting alternative for gene therapy in all ocular compartments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Entry and integration of HIV-1. Structural and enzymatic HIV-1 genes are presented in gray boxes, HIV-1 regulatory factors in green, HIV-1 accessory factors in blue, and LTR in yellow. Corresponding proteins are represented with the same color code in a schematic HIV-1 particle. The different processes, from binding to the cell membrane to the integration of the provirus DNA into the host genome, are depicted with viral protein required at each step. The timing of uncoating of the capsid (CA) and the role of CA is still unclear, as discussed in a recent review [11]. The Gag gene codes for matrix proteins (MA), capsid proteins (CA), and nucleocapsid protein (NC). The Pol gene encodes for the reverse transcriptase (RT), the integrase (IN), and the protease (PRO).](https://figures.cochat.ai/paper-figures/f17286d4d038409bb4bfc035d2358af9/lentiviral-vectors-for-ocular-gene-therapy-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, they carry risks for insertional mutagenesis and germline transmission and may elicit more inflammatory responses than AAVs.54,56,73”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 1×
“Then the SA, SD, cPPT, and RRE sequences are essential for the preparation and packaging of the transfer cassette into the recombinant viral particle and its import into the host cell nuclei [3,7].”
BackgroundProgrammable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184 · cited 1×
“New editing strategies, based on modified Cas9, allow for specifically replacing a cytosine or an adenine without inducing DNA double-strand break [156].”
BackgroundLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587 · cited 1×
“Indeed, since one of its first use in human clinics, gene therapy using retroviruses (Moloney retrovirus), despite showing at first an impressive efficiency, is unfortunately followed by a lethal risk of mutational insertion [23,24].”
BackgroundGene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Indeed, since one of its first use in human clinics, gene therapy using retroviruses (Moloney retrovirus), despite showing at first an impressive efficiency, is unfortunately followed by a lethal risk of mutational insertion [23,24].”
BackgroundInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854 · cited 1×
“This indicates that, unlike other retroviruses (gammaretroviral vectors [29]), LV insertional mutation event is a risk low enough to support the safety of LV for clinical use.”
BackgroundSelf-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis
Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E., Xu, H.-J., Benedict, W., & Bouck, N. P. (1999) · Science · doi:10.1126/science.285.5425.245 · Cited by 1,505 · cited 1×
“PEDF has both anti-angiogenic and neuroprotective actions [135,136].”
BackgroundNaldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276 · cited 1×
“Moreover, recombination at the post-transcriptional level, for example, between splicing sites of the viral RNA and the host RNAs, is another treatment to consider [19], even if it can sometimes be beneficial for the treatment [20].”
BackgroundDefective myosin VIIA gene responsible for Usher syndrome type IB
Well, D., Blanchard, S., Kaplan, J., Guilford, P., Gibson, F., Walsh, J., Mburu, P., Varela, A., Levilliers, J., Weston, M. D., et al. (1995) · Nature · doi:10.1038/374060a0 · Cited by 1,068 · cited 1×
“The shaker1 mouse model partially recapitulates the disease with congenital deafness appearance and vestibular dysfunction due to mutations in the Myo7a gene [159].”
BackgroundOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051 · cited 1×
“While gene transactivation following viral genome insertion has rarely benefited the cells, providing, for example, a proliferative advantage to the transduced cells [22], it is more often seen as a threat.”
BackgroundZufferey, R., Donello, J. E., Trono, D., & Hope, T. J. (1999) · Journal of Virology · doi:10.1128/jvi.73.4.2886-2892.1999 · Cited by 1,014 · cited 1×
“Optionally, to increase the transgene expression efficiency, the woodchuck hepatitis virus post-transcriptional regulatory element is often introduced in 3′ of the transgene [35].”
BackgroundHIV-1: Fifteen Proteins and an RNA
Frankel, A. D., & Young, J. A. T. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.1 · Cited by 920 · cited 1×
“To efficiently transduce a target cell, the lentiviral genome is composed of the following coding genes [10]:”
BackgroundHIV-1 Genome Nuclear Import Is Mediated by a Central DNA Flap
Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L., & Charneau, P. (2000) · Cell · doi:10.1016/s0092-8674(00)80828-4 · Cited by 833 · cited 2×
“Then the SA, SD, cPPT, and RRE sequences are essential for the preparation and packaging of the transfer cassette into the recombinant viral particle and its import into the host cell nuclei [3,7].”
BackgroundBukrinsky, M. I., Haggerty, S., Dempsey, M. P., Sharova, N., Adzhubei, A., Spitz, L., Lewis, P., Goldfarb, D., Emerman, M., & Stevenson, M. (1993) · Nature · doi:10.1038/365666a0 · Cited by 802 · cited 1×
“Compared to other retroviruses, lentiviruses have the ability to infect non-dividing cells thanks to the import of their pre-integration complex to the nuclear compartment [1].”
BackgroundCorneal avascularity is due to soluble VEGF receptor-1
Ambati, B. K., Nozaki, M., Singh, N., Takeda, A., Jani, P. D., Suthar, T., Albuquerque, R. J. C., Richter, E., Sakurai, E., Newcomb, M. T., et al. (2006) · Nature · doi:10.1038/nature05249 · Cited by 684 · cited 1×
“Cornea also secretes soluble Flt1-receptor to prevent the vascularization of the cornea from the conjunctiva [193].”
BackgroundGal, A., Li, Y., Thompson, D. A., Weir, J., Orth, U., Jacobson, S. G., Apfelstedt-Sylla, E., & Vollrath, D. (2000) · Nature Genetics · doi:10.1038/81555 · Cited by 679 · cited 1×
“The first model presents a deficiency, due to a mutation in the Mertk gene, of RPE function to phagocyte photoreceptor outer segment debris (each photoreceptor continuously loses outer segment fragments), leading to photoreceptor debris accumulation and progressive photoreceptor death [168,169].”
BackgroundA role for LEDGF/p75 in targeting HIV DNA integration
Ciuffi, A., Llano, M., Poeschla, E., Hoffmann, C., Leipzig, J., Shinn, P., Ecker, J. R., & Bushman, F. (2005) · Nature Medicine · doi:10.1038/nm1329 · Cited by 658
LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus
Finkelshtein, D., Werman, A., Novick, D., Barak, S., & Rubinstein, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214441110 · Cited by 656
Genetic Reactivation of Cone Photoreceptors Restores Visual Responses in Retinitis Pigmentosa
Busskamp, V., Duebel, J., Balya, D., Fradot, M., Viney, T. J., Siegert, S., Groner, A. C., Cabuy, E., Forster, V., Seeliger, M., et al. (2010) · Science · doi:10.1126/science.1190897 · Cited by 642 · cited 1×
“Lipinski’s study suggested that VSV-G targeting of photoreceptors could be species-dependent since a VSV-G pseudotyped vector could transduce cells of the outer nuclear layer (ONL) when incubated on humans but not on murine explants [100,105].”
BackgroundSustained expression of genes delivered directly into liver and muscle by lentiviral vectors
Kafri, T., Blömer, U., Peterson, D. A., Gage, F. H., & Verma, I. M. (1997) · Nature Genetics · doi:10.1038/ng1197-314 · Cited by 605
The molecular basis of human retinal and vitreoretinal diseases
Berger, W., Kloeckener-Gruissem, B., & Neidhardt, J. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.03.004 · Cited by 594 · cited 1×
“More than 400 altered genes were identified to be causative for IRD, which englobe Leber congenital amaurosis, retinitis pigmentosa, night blindness, Usher syndrome, Stargardt disease, cone-rod dystrophies, Bardet-Biedl syndrome, and several others [151].”
BackgroundDesigned Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Plückthun, A. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134654 · Cited by 575
May, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567
Mey, J., & Thanos, S. (1993) · Brain Research · doi:10.1016/0006-8993(93)90695-j · Cited by 547
Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells.
Yu, S. F., von Rüden, T., Kantoff, P. W., Garber, C., Seiberg, M., Rüther, U., Anderson, W. F., Wagner, E. F., & Gilboa, E. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.10.3194 · Cited by 541
Pfeifer, A., Ikawa, M., Dayn, Y., & Verma, I. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251682798 · Cited by 522
Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa
Punzo, C., Kornacker, K., & Cepko, C. L. (2009) · Nature Neuroscience · doi:10.1038/nn.2234 · Cited by 514
Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector
Miyoshi, H., Takahashi, M., Gage, F. H., & Verma, I. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10319 · Cited by 494 · cited 1×
“Replacement of the HIV-1 promoter sequence of the 5′LTR by a CMV promoter also increases the amount of transcription of the recombinant genome and thus the recombinant viral particle production [32,33,57].”
BackgroundEffective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460 · cited 1×
“Additionally, the use of integrative-deficient LV (IDLV) can also be an efficient alternative for non-dividing cells [51,52].”
Chapter 5 Generation of High-Titer Pseudotyped Retroviral Vectors with Very Broad Host Range
Yee, J.-K., Friedmann, T., & Burns, J. C. (1994) · Methods in Cell Biology · doi:10.1016/s0091-679x(08)60600-7 · Cited by 448
Cideciyan, A. V., Jacobson, S. G., Beltran, W. A., Sumaroka, A., Swider, M., Iwabe, S., Roman, A. J., Olivares, M. B., Schwartz, S. B., Komáromy, A. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218933110 · Cited by 444 · cited 1×
“In addition, for certain diseases, a gene replacement treatment at a late disease stage did not prevent retinal degeneration, although the visual function was ameliorated [167].”
BackgroundRamon, P. P., Salvador, M., Villegas-Pérez, M. P., & Vidal‐Sanz, M. (1996) · PubMed · Cited by 441
Identification and characterization of rod-derived cone viability factor
Léveillard, T., Mohand-Saïd, S., Lorentz, O., Hicks, D., Fintz, A.-C., Clérin, E., Simonutti, M., Forster, V., Cavusoglu, N., Chalmel, F., et al. (2004) · Nature Genetics · doi:10.1038/ng1386 · Cited by 438
Rod-Derived Cone Viability Factor Promotes Cone Survival by Stimulating Aerobic Glycolysis
Aït-Ali, N., Fridlich, R., Millet-Puel, G., Clérin, E., Delalande, F., Jaillard, C., Blond, F., Perrocheau, L., Reichman, S., Byrne, L. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.023 · Cited by 434
Mazarakis, N. D. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.19.2109 · Cited by 426 · cited 1×
“Rabies-G interacts with neuronal receptors, including neural cell adhesion molecule (NCAM) [110], nicotinic acetylcholine receptor [111–113], and the p75 low-affinity neurotrophin receptor (p75NTR) [114] and shows efficient targeting and retrograde transport in the brain [115].”
BackgroundIshida, S., Usui, T., Yamashiro, K., Kaji, Y., Amano, S., Ogura, Y., Hida, T., Oguchi, Y., Ambati, J., Miller, J. W., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022027 · Cited by 421 · cited 2×
“Because the VEGF164 variant is often associated with inflammation and pathological conditions [148], targeting this variant may be beneficial for ROP treatment by modifying the disease course evolution without altering VEGFA-dependent retinal development.”
BackgroundMethodPoeschla, E. M., Wong-Staal, F., & Looney, D. J. (1998) · Nature Medicine · doi:10.1038/nm0398-354 · Cited by 416 · cited 1×
“Replacement of the HIV-1 promoter sequence of the 5′LTR by a CMV promoter also increases the amount of transcription of the recombinant genome and thus the recombinant viral particle production [32,33,57].”
BackgroundAuricchio, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.26.3075 · Cited by 403 · cited 1×
“The Mokola virus envelope was also used in the retina to strongly target the RPE [106,107] but also Müller cells in degenerating conditions [98].”
MethodEpidemiology of blindness in children
Solebo, A. L., Teoh, L., & Rahi, J. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2016-310532 · Cited by 383 · cited 1×
“This retinopathy of prematurity (ROP) is a leading cause of childhood vision loss and blindness worldwide [143].”
BackgroundThe Neural Cell Adhesion Molecule Is a Receptor for Rabies Virus
Thoulouze, M.-I., Lafage, M., Schachner, M., Hartmann, U., Cremer, H., & Lafon, M. (1998) · Journal of Virology · doi:10.1128/jvi.72.9.7181-7190.1998 · Cited by 379 · cited 1×
“Rabies-G interacts with neuronal receptors, including neural cell adhesion molecule (NCAM) [110], nicotinic acetylcholine receptor [111–113], and the p75 low-affinity neurotrophin receptor (p75NTR) [114] and shows efficient targeting and retrograde transport in the brain [115].”
BackgroundMettu, P. S., Allingham, M. J., & Cousins, S. W. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100906 · Cited by 370 · cited 2×
“Several angiogenic factors were then identified to be responsible for CNV growth, such as vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF), leading to the development of efficient drugs to block and even regress CNV evolution [129].”
BackgroundTravis, G. H., Sutcliffe, J. G., & Bok, D. (1991) · Neuron · doi:10.1016/0896-6273(91)90122-g · Cited by 325 · cited 1×
“The second model is the Rds mouse, which presents a defect in the structural protein peripherin [170,171].”
BackgroundLentiviruses as gene transfer agents for delivery to non-dividing cells
Naldini, L. (1998) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(98)80029-3 · Cited by 303
Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus
Tuffereau, C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7250 · Cited by 300 · cited 1×
“Rabies-G interacts with neuronal receptors, including neural cell adhesion molecule (NCAM) [110], nicotinic acetylcholine receptor [111–113], and the p75 low-affinity neurotrophin receptor (p75NTR) [114] and shows efficient targeting and retrograde transport in the brain [115].”
BackgroundDeglon, N., Tseng, J. L., Bensadoun, J.-C., Zurn, A. D., Arsenijevic, Y., Almeida, L. P. D., Zufferey, R., Trono, D., & Aebischer, P. (2000) · Human Gene Therapy · doi:10.1089/10430340050016256 · Cited by 292 · cited 1×
“To bypass the problematic of multiple injections to protect RGC, a SIN HIV-derived LV [187] was tested in a rat model of optic nerve axotomy [96].”
Connell, G., Bascom, R., Molday, L., Reid, D., McInnes, R. R., & Molday, R. S. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.723 · Cited by 289 · cited 1×
“The second model is the Rds mouse, which presents a defect in the structural protein peripherin [170,171].”
BackgroundHIV Integrase, a Brief Overview from Chemistry to Therapeutics
Craigie, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100027200 · Cited by 258 · cited 2×
“The integration process is the result of several steps: vector 3′-end modification, opening of host genome and insertion of viral DNA, gap repair, and ligation [13].”
BackgroundRescue and propagation of fully retargeted oncolytic measles viruses
Nakamura, T., Peng, K.-W., Harvey, M., Greiner, S., Lorimer, I. A. J., James, C. D., & Russell, S. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1060 · Cited by 252
Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein
Nikolic, J., Belot, L., Raux, H., Legrand, P., Gaudin, Y., & A. Albertini, A. (2018) · Nature Communications · doi:10.1038/s41467-018-03432-4 · Cited by 241
The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication
Engelman, A., & Cherepanov, P. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000046 · Cited by 231
Integration-deficient Lentiviral Vectors: A Slow Coming of Age
Wanisch, K., & Yáñez-Muñoz, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.122 · Cited by 222 · cited 1×
“This transient expression can be seen as an advantage in some conditions, such as CRISPR/Cas9-mediated gene editing [49], vaccination, or induction of recombination [50].”
BackgroundLentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection
Morizono, K., Xie, Y., Ringpis, G.-E., Johnson, M., Nassanian, H., Lee, B., Wu, L., & Chen, I. S. Y. (2005) · Nature Medicine · doi:10.1038/nm1192 · Cited by 220
Targeted Cell Entry of Lentiviral Vectors
Funke, S., Maisner, A., Mühlebach, M. D., Koehl, U., Grez, M., Cattaneo, R., Cichutek, K., & Buchholz, C. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.128 · Cited by 218
Kong, J., Kim, S.-R., Binley, K., Pata, I., Doi, K., Mannik, J., Zernant-Rajang, J., Kan, O., Iqball, S., Naylor, S., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.78 · Cited by 215 · cited 2×
“0× 105 TU) allowed the transduction of around 5% of photoreceptors as well as RPE and some Müller cells in the treated area [161].”
BackgroundThe Interaction of LEDGF/p75 with Integrase Is Lentivirus-specific and Promotes DNA Binding
Busschots, K., Vercammen, J., Emiliani, S., Benarous, R., Engelborghs, Y., Christ, F., & Debyser, Z. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411681200 · Cited by 208
Takahashi, M., Miyoshi, H., Verma, I. M., & Gage, F. H. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7812-7816.1999 · Cited by 207 · cited 1×
“Young animals were subretinally injected at PN2 to 5 with LV-Rhop-GFP or LV-Rhop-Pde6b (around 5 × 105 TU) [152].”
MethodHindmarsh, P., & Leis, J. (1999) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.63.4.836-843.1999 · Cited by 202 · cited 1×
“Integration is mediated by IN encoded in the viral pol gene and cleaved by PRO from the Gag-Pol polyprotein [12].”
BackgroundLentiviral Gene Transfer to the Nonhuman Primate Brain
Kordower, J. H., Bloch, J., Ma, S. Y., Chu, Y., Palfi, S., Roitberg, B. Z., Emborg, M., Hantraye, P., Déglon, N., & Aebischer, P. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7178 · Cited by 199
Amirache, F., Lévy, C., Costa, C., Mangeot, P.-E., Torbett, B. E., Wang, C. X., Nègre, D., Cosset, F.-L., & Verhoeyen, E. (2014) · Blood · doi:10.1182/blood-2013-11-540641 · Cited by 197
Roles of IL-8 in Ocular Inflammations: A Review
Ghasemi, H., Ghazanfari, T., Yaraee, R., Faghihzadeh, S., & Hassan, Z. M. (2011) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2011.618902 · Cited by 195
Transient Gene Expression by Nonintegrating Lentiviral Vectors
Nightingale, S. J., Hollis, R. P., Pepper, K. A., Petersen, D., Yu, X.-J., Yang, C., Bahner, I., & Kohn, D. B. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.008 · Cited by 192 · cited 5×
“Additionally, the use of integrative-deficient LV (IDLV) can also be an efficient alternative for non-dividing cells [51,52].”
MethodInfluentialCui, Q., Lü, Q., So, K., & Yip, H. K.-F. (1999) · PubMed · Cited by 187
Self-Inactivating Lentiviral Vectors with U3 and U5 Modifications
Iwakuma, T., Cui, Y., & Chang, L.-J. (1999) · Virology · doi:10.1006/viro.1999.9850 · Cited by 187 · cited 1×
“Replacement of the HIV-1 promoter sequence of the 5′LTR by a CMV promoter also increases the amount of transcription of the recombinant genome and thus the recombinant viral particle production [32,33,57].”
BackgroundLentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study
Campochiaro, P. A., Lauer, A. K., Sohn, E. H., Mir, T. A., Naylor, S., Anderton, M. C., Kelleher, M., Harrop, R., Ellis, S., & Mitrophanous, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.117 · Cited by 186 · cited 1×
“These promising data resulted in the launch of a phase I/IIa clinical trial (NCT01301443) to explore the safety of the vector and identify potential benefits [142].”
BackgroundMerten, O.-W., Charrier, S., Laroudie, N., Fauchille, S., Dugué, C., Jenny, C., Audit, M., Zanta-Boussif, M.-A., Chautard, H., Radrizzani, M., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.060 · Cited by 185 · cited 1×
“Transfection of packaging plasmid(s) is widely used in laboratories for basic or preclinical research but also to prepare vectors for clinical applications [61].”
BackgroundMoiani, A., Paleari, Y., Sartori, D., Mezzadra, R., Miccio, A., Cattoglio, C., Cocchiarella, F., Lidonnici, M. R., Ferrari, G., & Mavilio, F. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61852 · Cited by 183 · cited 1×
“Moreover, recombination at the post-transcriptional level, for example, between splicing sites of the viral RNA and the host RNAs, is another treatment to consider [19], even if it can sometimes be beneficial for the treatment [20].”
BackgroundComprehensive genomic access to vector integration in clinical gene therapy
Gabriel, R., Eckenberg, R., Paruzynski, A., Bartholomae, C. C., Nowrouzi, A., Arens, A., Howe, S. J., Recchia, A., Cattoglio, C., Wang, W., et al. (2009) · Nature Medicine · doi:10.1038/nm.2057 · Cited by 182 · cited 1×
“Several approaches to determine both the integration site and the vector copy number per cell have been developed and recently improved, ranging from optimized linear amplification-mediated PCR (LAM-PCR) [25] to enhanced-specificity tagmentation-assisted PCR (esTag-PCR) [26] or digital droplet PCR (ddPCR), associated…”
MethodLing, S., Yang, S., Hu, X., Yin, D., Dai, Y., Qian, X., Wang, D., Pan, X., Hong, J., Sun, X., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00656-y · Cited by 179 · cited 12×
“Following validation of the vector safety in rabbit eyes, 21 patients with advanced neovascular AMD were enrolled and injected with increasing vector doses.”
BackgroundInfluentialEffects of GDNF on retinal ganglion cell survival following axotomy
Koeberle, P. D., & Ball, A. K. (1998) · Vision Research · doi:10.1016/s0042-6989(97)00364-7 · Cited by 168
Suh, S., Choi, E. H., Leinonen, H., Foik, A. T., Newby, G. A., Yeh, W.-H., Dong, Z., Kiser, P. D., Lyon, D. C., Liu, D. R., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00632-6 · Cited by 163 · cited 1×
“An adenine base editor (ABE, consisting of a Cas9 without DNAse activity fused to an adenosine deaminase) carried by an LV was used to correct a Rpe65 gene mutation in the Rd12 mouse model, which has a stop codon imposed by an adenine mutation [157].”
MethodAnliker, B., Abel, T., Kneissl, S., Hlavatý, J., Caputi, A., Brynza, J., Schneider, I. C., Münch, R. C., Petznek, H., Kontermann, R. E., et al. (2010) · Nature Methods · doi:10.1038/nmeth.1514 · Cited by 159
de Almeida, L. P., Zala, D., Aebischer, P., & Déglon, N. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0388 · Cited by 156 · cited 1×
“This LV coding for CNTF had already shown its neuroprotective effect in a rat model of Huntington’s disease [188].”
BackgroundNowell, C. S., Odermatt, P. D., Azzolin, L., Hohnel, S., Wagner, E. F., Fantner, G. E., Lutolf, M. P., Barrandon, Y., Piccolo, S., & Radtke, F. (2016) · Nature Cell Biology · doi:10.1038/ncb3290 · Cited by 154 · cited 1×
“For instance, inflammation may transform corneal epithelial cells to epidermal cell fate [191].”
BackgroundEpisomal vectors for gene expression in mammalian cells
Van Craenenbroeck, K., Vanhoenacker, P., & Haegeman, G. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01645.x · Cited by 147
Manilla, P., Rebello, T., Afable, C., Lu, X., Slepushkin, V., Humeau, L. M., Schonely, K., Ni, Y., Binder, G. K., Levine, B. L., et al. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.17 · Cited by 147 · cited 1×
“Nevertheless, if some lentivirus particularities can be seen as a clear benefit to broaden the range of gene therapy applications, they become a threat in a safety context [9].”
BackgroundTrabecular Repopulation by Anterior Trabecular Meshwork Cells After Laser Trabeculoplasty
Samples, J. R., Bradley, J. M. B., Bacon, D. R., Bylsma, S., Buskirk, E. M. V., & Acott, T. S. (1989) · American Journal of Ophthalmology · doi:10.1016/0002-9394(89)90805-2 · Cited by 147 · cited 1×
“Previous studies have shown proliferating cells in the trabecular meshwork suggesting a renewal capacity of these cells [174].”
BackgroundCroyle, M. A., Callahan, S. M., Auricchio, A., Schumer, G., Linse, K. D., Wilson, J. M., Brunner, L. J., & Kobinger, G. P. (2004) · Journal of Virology · doi:10.1128/jvi.78.2.912-921.2004 · Cited by 147 · cited 2×
“modified the VSV-G envelope with PEGylation to decrease the complement inactivation of the recombinant vectors from human and mouse sera, which increased vector efficiency to target bone marrow and spleen [103].”
BackgroundMethodOrtinski, P. I., O’Donovan, B., Dong, X., & Kantor, B. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.002 · Cited by 146 · cited 1×
“This transient expression can be seen as an advantage in some conditions, such as CRISPR/Cas9-mediated gene editing [49], vaccination, or induction of recombination [50].”
BackgroundBushman, F. D. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.009 · Cited by 146 · cited 1×
“Four different mechanisms have recently been described as retroviral insertional mutagenesis in humans [21].”
BackgroundTucci, F., Galimberti, S., Naldini, L., Valsecchi, M. G., & Aiuti, A. (2022) · Nature Communications · doi:10.1038/s41467-022-28762-2 · Cited by 145 · cited 1×
“Following successful use for ex vivo approaches, mainly for hematopoietic diseases [85], the continuous development of lentiviral production and safety assessment now provide reliable tools to make LV attractive for in vivo clinical application.”
MethodPugazhendhi, A., Hubbell, M., Jairam, P., & Ambati, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031170 · Cited by 141 · cited 1×
“Antiangiogenic therapies have been successful now for 12 years, by delaying neovessel development for years and by efficiently protecting the retina [131].”
BackgroundNandrot, E., Dufour, E. M., Provost, A. C., Péquignot, M. O., Bonnel, S., Gogat, K., Marchant, D., Rouillac, C., Sépulchre de Condé, B., Bihoreau, M.-T., et al. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0328 · Cited by 139 · cited 1×
“The first model presents a deficiency, due to a mutation in the Mertk gene, of RPE function to phagocyte photoreceptor outer segment debris (each photoreceptor continuously loses outer segment fragments), leading to photoreceptor debris accumulation and progressive photoreceptor death [168,169].”
BackgroundDevelopment of a Novel Trans-Lentiviral Vector That Affords Predictable Safety
Wu, X., Wakefield, J. K., Liu, H., Xiao, H., Kralovics, R., Prchal, J. T., & Kappes, J. C. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0095 · Cited by 137 · cited 3×
“In addition, other systems were developed to minimize RCLs, such as Rev-independent LV [44] or a five plasmids trans-lentiviral system, which separates the RT-IN from the Gag-Pol [45,46].”
MethodKlebe, S., Sykes, P. J., Coster, D. J., Krishnan, R., & Williams, K. A. (2001) · Transplantation · doi:10.1097/00007890-200105150-00006 · Cited by 136 · cited 1×
“Indeed, the use of an adeno-viral vector to transduce the cornea allowed a tremendous production of IL-10, up to more than 103 times those obtained with the LV vector in similar conditions, and prolonged the graft survival by 35 days [200] instead of 7 days with the LV.”
MethodDARPins: An Efficient Targeting Domain for Lentiviral Vectors
Münch, R. C., Mühlebach, M. D., Schaser, T., Kneissl, S., Jöst, C., Plückthun, A., Cichutek, K., & Buchholz, C. J. (2011) · Molecular Therapy · doi:10.1038/mt.2010.298 · Cited by 130
Segura, M. M., Garnier, A., Durocher, Y., Coelho, H., & Kamen, A. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21467 · Cited by 130 · cited 1×
“LVs are mainly collected using a heparin column, but the elution is also dependent on salt concentration and requires an additional step such as a TFF for buffer exchange [58,69].”
BackgroundLentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B
Hashimoto, T., Gibbs, D., Lillo, C., Azarian, S. M., Legacki, E. L., Zhang, X., Yang, X.-J., & Williams, D. S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302897 · Cited by 125 · cited 1×
“Interestingly, melanosomes in cultured shaker1 RPE migrated in the cells with detours, whereas in the WT RPE, melanosomes followed a straightforward path [160].”
BackgroundMendell, J. R., Connolly, A. M., Lehman, K. J., Griffin, D. A., Khan, S. Z., Dharia, S. D., Quintana-Gallardo, L., & Rodino-Klapac, L. R. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.02.011 · Cited by 124 · cited 1×
“the immune system, and anti-inflammatory treatments are still largely used for human delivery [203,204].”
BackgroundApproaches for corneal endothelium regenerative medicine
Català, P., Thuret, G., Skottman, H., Mehta, J. S., Parekh, M., Dhubhghaill, S. N., Collin, R. W. J., Nuijts, R. M. M. A., Ferrari, S., LaPointe, V. L. S., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100987 · Cited by 123 · cited 1×
“Despite the argument of the authors that no tumor formation has been reported from corneal endothelial cells, the vector safety of Bclx-xL may be questionable since the proliferation of corneal endothelial cells can still be observed in vitro (for review [196]).”
BackgroundTaniwaki, T., Hirashima, N., Becerra, S. P., Chader, G. J., Etcheberrigaray, R., & Schwartz, J. P. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68010026.x · Cited by 118 · cited 1×
“PEDF has both anti-angiogenic and neuroprotective actions [135,136].”
BackgroundBemelmans, A.-P., Kostic, C., Crippa, S. V., Hauswirth, W. W., Lem, J., Munier, F. L., Seeliger, M. W., Wenzel, A., & Arsenijevic, Y. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030347 · Cited by 117 · cited 1×
“A linear relationship between the treated area and the surrounding rescued area can be determined and may serve in the future to treat the macula without the need for macular detachment to avoid damage due to the injection [153].”
BackgroundSelf-citationMechanisms Governing Lentivirus Integration Site Selection
Ciuffi, A. (2008) · Current Gene Therapy · doi:10.2174/156652308786848021 · Cited by 117 · cited 1×
“It has been previously shown that lentiviruses, unlike other retroviruses, preferentially integrate into active transcription units, the integration site being supposedly influenced by chromatin accessibility, cell cycle effects, and tethering mechanism [14].”
New developments in lentiviral vector design, production and purification
Segura, M. M., Mangion, M., Gaillet, B., & Garnier, A. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.779249 · Cited by 117
Interaction of Human Immunodeficiency Virus-Derived Vectors with Wild-Type Virus in Transduced Cells
Bukovsky, A. A., Song, J.-P., & Naldini, L. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.7087-7092.1999 · Cited by 116 · cited 1×
“2, has been rapidly adopted in the field of gene therapy, the risk of recombination with wild-type lentivirus still exists [18].”
BackgroundBinley, K., Widdowson, P., Loader, J., Kelleher, M., Iqball, S., Ferrige, G., de Belin, J., Carlucci, M., Angell-Manning, D., Hurst, F., et al. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11871 · Cited by 115 · cited 2×
“The group that validated RetinoStat in rabbits and macaques (see above) also measured the safety and biodistribution of a VSV-G pseudotyped EIAV-based lentiviral vector carrying a coding sequence for the ABCA4 gene injected subretinally in rabbits and macaques, in a context of gene therapy for Stargardt disease [76].”
Methodvan Adel, B. A., Kostic, C., Déglon, N., Ball, A. K., & Arsenijevic, Y. (2003) · Human Gene Therapy · doi:10.1089/104303403321070801 · Cited by 115 · cited 1×
“To bypass the problematic of multiple injections to protect RGC, a SIN HIV-derived LV [187] was tested in a rat model of optic nerve axotomy [96].”
Self-citationLentivirus Vector Gene Expression during ES Cell-Derived Hematopoietic Development In Vitro
Hamaguchi, I., Woods, N.-B., Panagopoulos, I., Andersson, E., Mikkola, H., Fahlman, C., Zufferey, R., Carlsson, L., Trono, D., & Karlsson, S. (2000) · Journal of Virology · doi:10.1128/jvi.74.22.10778-10784.2000 · Cited by 109
Zallocchi, M., Binley, K., Lad, Y., Ellis, S., Widdowson, P., Iqball, S., Scripps, V., Kelleher, M., Loader, J., Miskin, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094272 · Cited by 102 · cited 4×
“, the maximum dose tolerated, induced the production of human MYO7A protein in RPE cells and photoreceptor segments [77].”
BackgroundMethodInfluentialJo, D. H., Song, D. W., Cho, C. S., Kim, U. G., Lee, K. J., Lee, K., Park, S. W., Kim, D., Kim, J. H., Kim, J.-S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax1210 · Cited by 102 · cited 1×
“Such an approach was used because a homology-directed repair (HDR) strategy was shown to be poorly efficient, with only 1% of corrections and Indel formations [158].”
MethodLentiviral Vectors: Their Molecular Design, Safety, and Use in Laboratory and Preclinical Research
Dropulić, B. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.058 · Cited by 98
Luna, C., Li, G., Qiu, J., Epstein, D. L., & González, P. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22476 · Cited by 96 · cited 1×
“MiR-146a is upregulated when trabecular meshwork cells are submitted to stress [179].”
BackgroundSegura, M. M., Kamen, A., Trudel, P., & Garnier, A. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20301 · Cited by 95 · cited 1×
“LVs are mainly collected using a heparin column, but the elution is also dependent on salt concentration and requires an additional step such as a TFF for buffer exchange [58,69].”
BackgroundGene Therapy in the Anterior Eye Segment
Amador, C., Shah, R., Ghiam, S., Kramerov, A. A., & Ljubimov, A. V. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210423084233 · Cited by 93 · cited 1×
“Gene therapy development for cornea has already been very well presented and discussed [190].”
BackgroundRabies virus binding to an acetylcholine receptor α‐subunit peptide
Lentz, T. L. (1990) · Journal of Molecular Recognition · doi:10.1002/jmr.300030205 · Cited by 92
Large-Scale Production of Pseudotyped Lentiviral Vectors Using Baculovirus GP64
Kumar, M., Bradow, B. P., & Zimmerberg, J. J. (2003) · Human Gene Therapy · doi:10.1089/10430340360464723 · Cited by 91 · cited 1×
“Therefore, researchers identified the baculovirus GP64 protein as an alternative envelope protein, which conserves a wide tropism because it functions as a fusion protein but can be safely and stably expressed for viral production [117,118].”
BackgroundLarge-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges
Martínez-Molina, E., Chocarro‐Wrona, C., Martínez‐Moreno, D., Marchal, J. A., & Boulaiz, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111051 · Cited by 91
Miyazaki, M., Ikeda, Y., Yonemitsu, Y., Goto, Y., Sakamoto, T., Tabata, T., Ueda, Y., Hasegawa, M., Tobimatsu, S., Ishibashi, T., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302028 · Cited by 85 · cited 1×
“SIV-hPEDF was evaluated in NHP following production based on co-transfection of four plasmids and ultracentrifugation-based concentration [79,80].”
MethodGenetic Modification of Human Trabecular Meshwork with Lentiviral Vectors
Loewen, N., Fautsch, M. P., Peretz, M., Bahler, C. K., Cameron, J. D., Johnson, D. H., & Poeschla, E. M. (2001) · Human Gene Therapy · doi:10.1089/10430340152677449 · Cited by 84 · cited 1×
“The first evidence that LV can transduce trabecular meshwork was obtained using an FIV vector in a human eye organ culture [101].”
Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors
Balaggan, K. S., Binley, K., Esapa, M., Iqball, S., Askham, Z., Kan, O., Tschernutter, M., Bainbridge, J. W. B., Naylor, S., & Ali, R. R. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.845 · Cited by 83 · cited 4×
“Interestingly, as suggested for other pseudotyped vectors, the local damage at the site of injection also widens the vectors targeting other cell types such as ganglion cells and increases photoreceptor transduction [38,95,104].”
BackgroundMethodInfluentialBrown, H. E. V., Chen, H., & Engelman, A. (1999) · Journal of Virology · doi:10.1128/jvi.73.11.9011-9020.1999 · Cited by 83 · cited 1×
“Two main strategies are possible to generate IDLV: (1) by introducing a mutation into the pol gene to specifically mutate the integrase without disturbing the other properties of IN or the other proteins arising from the same gene, or (2) by mutating the integrase DNA attachment site [53,54].”
MethodGastka, M., Horvath, J., & Lentz, T. L. (1996) · Journal of General Virology · doi:10.1099/0022-1317-77-10-2437 · Cited by 82
Schauber, C., Tuerk, M., Pacheco, C. D., Escarpe, P., & Veres, G. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302170 · Cited by 79 · cited 1×
“Therefore, researchers identified the baculovirus GP64 protein as an alternative envelope protein, which conserves a wide tropism because it functions as a fusion protein but can be safely and stably expressed for viral production [117,118].”
BackgroundKostic, C., Chiodini, F., Salmon, P., Wiznerowicz, M., Déglon, N., Hornfeld, D., Trono, D., Aebischer, P., Schorderet, D. F., Munier, F. L., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301948 · Cited by 79 · cited 3×
“Interestingly, as suggested for other pseudotyped vectors, the local damage at the site of injection also widens the vectors targeting other cell types such as ganglion cells and increases photoreceptor transduction [38,95,104].”
BackgroundSelf-citationGrüter, O., Kostic, C., Crippa, S. V., Perez, M.-T. R., Zografos, L., Schorderet, D. F., Munier, F. L., & Arsenijévic, Y. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302485 · Cited by 78 · cited 6×
“Interestingly, as suggested for other pseudotyped vectors, the local damage at the site of injection also widens the vectors targeting other cell types such as ganglion cells and increases photoreceptor transduction [38,95,104].”
BackgroundSelf-citationHighly efficient large-scale lentiviral vector concentration by tandem tangential flow filtration
Cooper, A. R., Patel, S., Senadheera, S., Plath, K., Kohn, D. B., & Hollis, R. P. (2011) · Journal of Virological Methods · doi:10.1016/j.jviromet.2011.06.019 · Cited by 76 · cited 1×
“TFF is based on size exclusion using membranes with 1 to 100 nm pores to separate serum proteins, DNA fragments, and other cell culture contaminants [67].”
LentiPro26: novel stable cell lines for constitutive lentiviral vector production
Tomás, H. A., Rodrigues, A. F., Carrondo, M. J. T., & Coroadinha, A. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-23593-y · Cited by 76
Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes?
Tornabene, P., & Trapani, I. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.220 · Cited by 76
Evidence from the anti-idiotypic network that the acetylcholine receptor is a rabies virus receptor
Hanham, C. A., Zhao, F., & Tignor, G. H. (1993) · Journal of Virology · doi:10.1128/jvi.67.1.530-542.1993 · Cited by 75
Cell signaling in regulation of the barrier integrity of the corneal endothelium
Srinivas, S. P. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.09.009 · Cited by 74 · cited 1×
“Dysfunction of stromal cells may lead to endothelial cell junction permeabilization with, as a consequence, edema formation [192].”
BackgroundKato, S., Kobayashi, K., & Kobayashi, K. (2014) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2014.02.015 · Cited by 74 · cited 1×
“When the Rabies-G ectodomain was used in such chimeric protein, LV production was improved [120,121].”
MethodLiu, X., Hu, Y., Filla, M. S., Gabelt, B. T., Peters, D. M. P., Brandt, C. R., & Kaufman, P. L. (2005) · PubMed · Cited by 74
Roles of IL-10 in Ocular Inflammations: A Review
Ghasemi, H., Ghazanfari, T., Yaraee, R., Owlia, P., Hassan, Z. M., & Faghihzadeh, S. (2012) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2012.723109 · Cited by 74 · cited 1×
“To counteract inflammation mediated by TNFα-secreting monocytes, an LV was designed to express the IL-10 [198], the most anti-inflammatory cytokine [199].”
BackgroundLesch, H. P., Laitinen, A., Peixoto, C., Vicente, T., Макконен, К. Ф., Laitinen, L., Pikkarainen, J. T., Samaranayake, H. D., Alves, P. M., Carrondo, M. J. T., et al. (2011) · Gene Therapy · doi:10.1038/gt.2010.162 · Cited by 73 · cited 1×
“The use of baculovirus to transfer the different constructs is also a successful alternative for LV production [63,64].”
MethodDropulic, B., Slepushkin, V., Chang, N., Gan, Y., Jiang, B., Deausen, E., Berlinger, D., Binder, G., Andre, K., & Humeau, L. (2003) · BioProcessing Journal · doi:10.12665/j25.dropulic · Cited by 73 · cited 1×
“For large-scale preparation, a final sizeexclusion chromatography allows to discard the contamination with small elements and isolate the larger vector particles [70].”
BackgroundHolmgaard, A., Askou, A. L., Benckendorff, J. N. E., Thomsen, E. A., Cai, Y., Bek, T., Mikkelsen, J. G., & Corydon, T. J. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.08.016 · Cited by 73 · cited 1×
“LV (HIV-derived) vectors were designed to express the Streptococcus pyrogenes (sp) Cas9 with GFP, which allows transduced cells isolation in order to quantify Indel generation [140].”
MethodLi, G., Luna, C., Qiu, J., Epstein, D. L., & Gonzalez, P. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-4874 · Cited by 72 · cited 1×
“to repress several genes associated with inflammation and senescence and reduce intracellular reactive species [178].”
BackgroundGreenberg, K. P., Geller, S. F., Schaffer, D. V., & Flannery, J. G. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-1570 · Cited by 68 · cited 1×
“Another study showed that an LV pseudotyped with the Ross River virus (RRV) envelope mainly targeted RPE cells when expressing a CMV-GFP cassette [108], while it is more efficient to transduce Müller cells in vitro than a VSV-G-vector when expressing a cassette containing the CD44 promoter, which restricts expression…”
BackgroundBárcia, R. N., Dana, M. R., & Kazlauskas, A. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01897.x · Cited by 67 · cited 1×
“Graft survival thus necessitates a tight control of the cornea environment and decreases in correlation with endothelial cell death [194].”
BackgroundPharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection
Semeraro, F., Morescalchi, F., Duse, S., Gambicorti, E., Cancarini, A., & Costagliola, C. (2015) · Current Drug Metabolism · doi:10.2174/1389200216666151001120831 · Cited by 67 · cited 1×
“Indeed, VEGF supports the survival of different neurons [132], and the constant inhibition of VEGFA may lead to a loss of vessel fenestration and thinning of the vasculature [133].”
BackgroundGross, D., Tedesco, N., Leborgne, C., & Ronzitti, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857276 · Cited by 65 · cited 1×
“the immune system, and anti-inflammatory treatments are still largely used for human delivery [203,204].”
BackgroundSchnittman, S. M., Lane, H. C., Roth, J., Burrows, A., Folks, T. M., Kehrl, J. H., Koenig, S., Berman, P. W., & Fauci, A. S. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.12.4181 · Cited by 63 · cited 1×
“Initial works used the native viral envelop encoded by the viral env gene, which, for HIV-1, is selective to CD4+ cells [4,5].”
MethodCachafeiro, M. C. B., Bemelmans, A., Samardzija, M., Afanasieva, T. A., Pournaras, J.-A., Grimm, C., Kostic, C., Philippe, S., Wenzel, A., & Arsenijévic, Y. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.303 · Cited by 61 · cited 1×
“A lentiviral vector expressing a single-chain antibody directed against VEGF (scFv V65) was also tested to prevent CNV formation after laser injury in the mouse retina [137].”
MethodSelf-citationBinley, K., Widdowson, P. S., Kelleher, M., de Belin, J., Loader, J., Ferrige, G., Carlucci, M., Esapa, M., Chipchase, D., Angell-Manning, D., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.008 · Cited by 61 · cited 5×
“element, which promotes the translation of a second protein from a unique mRNA [36], or by the 2A element, which mediates the cleavage of two proteins from the same mRNA [37].”
BackgroundMethodInfluentialSastry, L., Xu, Y., Johnson, T., Desai, K., Rissing, D., Marsh, J., & Cornetta, K. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.08.003 · Cited by 60 · cited 1×
“Moreover, no RCLs were identified with the third generation of LV, validating the use of the four plasmid systems for therapeutic purposes [42,47].”
BackgroundDesign and potential of non-integrating lentiviral vectors
Shaw, A., & Cornetta, K. (2014) · Biomedicines · doi:10.3390/biomedicines2010014 · Cited by 60 · cited 1×
“Two main strategies are possible to generate IDLV: (1) by introducing a mutation into the pol gene to specifically mutate the integrase without disturbing the other properties of IN or the other proteins arising from the same gene, or (2) by mutating the integrase DNA attachment site [53,54].”
MethodParker, M. A., Erker, L. R., Audo, I., Choi, D., Mohand-Said, S., Sestakauskas, K., Benoit, P., Appelqvist, T., Krahmer, M., Ségaut-Prévost, C., et al. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.02.013 · Cited by 60
Mundell, N. A., Beier, K. T., Pan, Y. A., Lapan, S. W., Göz Aytürk, D., Berezovskii, V. K., Wark, A. R., Drokhlyansky, E., Bielecki, J., Born, R. T., et al. (2015) · Journal of Comparative Neurology · doi:10.1002/cne.23761 · Cited by 59 · cited 1×
“Moreover, retrograde transport was also observed from brain to retina (RGCs, Müller cells, and amacrine cells) in the developing chicken after injection of these rabies-G EIAV vectors [116].”
BackgroundHirano, M., Kato, S., Kobayashi, K., Okada, T., Yaginuma, H., & Kobayashi, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075896 · Cited by 58 · cited 1×
“When the Rabies-G ectodomain was used in such chimeric protein, LV production was improved [120,121].”
MethodRetinal transduction profiles by high-capacity viral vectors
Puppo, A., Cesi, G., Marrocco, E., Piccolo, P., Jacca, S., Shayakhmetov, D. M., Parks, R. J., Davidson, B. L., Colloca, S., Brunetti-Pierri, N., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.57 · Cited by 56 · cited 3×
“Strikingly, this targeting could be reproduced with the use of a Rhodopsin promoter [108].”
BackgroundReplication-competent Lentivirus Analysis of Clinical Grade Vector Products
Cornetta, K., Yao, J., Jasti, A., Koop, S., Douglas, M., Hsu, D., Couture, L. A., Hawkins, T., & Duffy, L. (2011) · Molecular Therapy · doi:10.1038/mt.2010.278 · Cited by 55
Klebe, S., Coster, D. J., Sykes, P. J., Swinburne, S. J., Hallsworth, P. G., Scheerlinck, J. Y., Krishnan, R., & Williams, K. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2219 · Cited by 54 · cited 1×
“One target could be, for example, the cell death-initiating factors such as cytokines [197].”
BackgroundWang, H., Smith, G. W., Yang, Z., Jiang, Y., McCloskey, M., Greenberg, K. P., Geisen, P., Culp, W. D., Flannery, J. G., Kafri, T., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.011 · Cited by 54 · cited 1×
“LV-CD44p-VEGFAshRNA-GFP specificity and efficiency in inhibiting VEGFA in Müller cells and preventing IVNV were first evaluated [146] and then compared to LV-CD44pVEGF164shRNA-GFP.”
ResultProstaglandin Pathway Gene Therapy for Sustained Reduction of Intraocular Pressure
Barraza, R. A., McLaren, J. W., & Poeschla, E. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.278 · Cited by 54 · cited 2×
“Prostaglandin synthesis depends on cyclooxygenase-2 (COX2) activity, so the possibility of boosting PGF2 expression was explored using FIV-derived vectors coding for COX2 in combination with PGF or prostaglandin F receptor (FPR, [176]).”
BackgroundJiang, Y., Wang, H., Culp, D., Yang, Z., Fotheringham, L., Flannery, J. G., Hammond, S. M., Kafri, T., & Hartnett, M. E. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13755 · Cited by 52 · cited 1×
“Since VEGF inhibition may induce retinal cell death [148,149], retinal activity was monitored with both focal ERG to study only the transduced area and full-field ERG to measure the whole retina activity.”
MethodGeneration of lentivirus vectors using recombinant baculoviruses
Lesch, H. P., Turpeinen, S., Niskanen, E. A., Mahonen, A., Airenne, K. J., & Ylä‐Herttuala, S. (2008) · Gene Therapy · doi:10.1038/gt.2008.76 · Cited by 52 · cited 1×
“The use of baculovirus to transfer the different constructs is also a successful alternative for LV production [63,64].”
MethodAskou, A. L., Aagaard, L., Kostic, C., Arsenijevic, Y., Hollensen, A. K., Bek, T., Jensen, T. G., Mikkelsen, J. G., & Corydon, T. J. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.64 · Cited by 52 · cited 1×
“The efficacy of the vector containing three miRNAs sequences integrated instead of the intron was validated in an in vitro model of endothelial cell tube formation dependent on VEGFA expression [138,139].”
BackgroundSelf-citationBecker, S., Wang, H., Simmons, A. B., Suwanmanee, T., Stoddard, G. J., Kafri, T., & Hartnett, M. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-20278-4 · Cited by 51 · cited 8×
“Lentiviral vectors (LV-CD44p-lucifshRNA-GFP in the control group) were subretinally injected at PN8, starting point of OIR [147].”
MethodInfluentialBemelmans, A.-P., Bonnel, S., Houhou, L., Dufour, N., Nandrot, E., Helmlinger, D., Sarkis, C., Abitbol, M., & Mallet, J. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.788 · Cited by 50 · cited 1×
“The Mokola virus envelope was also used in the retina to strongly target the RPE [106,107] but also Müller cells in degenerating conditions [98].”
MethodDurable, Safe, Multi-gene Lentiviral Vector Expression in Feline Trabecular Meshwork
Khare, P. D., Loewen, N. A., Teo, W., Barraza, R., Saenz, D. T., Johnson, D. H., & Poeschla, E. M. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300318 · Cited by 50 · cited 13×
“The intracameral (in the anterior chamber) injection of 4 × 106 TU of FIV-C3-GFP in the rat eye led to a marked transduction of cells within the Schlemm’s canal region.”
MethodInfluentialZimmermann, K., Scheibe, O., Kocourek, A., Muelich, J., Jurkiewicz, E., & Pfeifer, A. (2011) · BMC Biotechnology · doi:10.1186/1472-6750-11-55 · Cited by 48 · cited 1×
“Anion-exchange chromatography uses a cationic column to select negatively charged LV particles; however, a high salt concentration is then needed to recover the particles, and this treatment can affect the transduction efficiency of the vector [68].”
BackgroundBarraza, R. A., Rasmussen, C. A., Loewen, N., Cameron, J. D., Gabelt, B. T., Teo, W.-L., Kaufman, P. L., & Poeschla, E. M. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.086 · Cited by 48 · cited 14×
“The intracameral (in the anterior chamber) injection of 4 × 106 TU of FIV-C3-GFP in the rat eye led to a marked transduction of cells within the Schlemm’s canal region.”
MethodInfluentialLoewen, N., Fautsch, M. P., Teo, W.-L., Bahler, C. K., Johnson, D. H., & Poeschla, E. M. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0366 · Cited by 46 · cited 1×
“The same group then presented the proof of concept that these cells can be efficiently targeted in vivo in cat eyes with 107 or 108 TU depending on the construct [102].”
BackgroundParker, M. A., Choi, D., Erker, L. R., Pennesi, M. E., Yang, P., Chegarnov, E. N., Steinkamp, P. N., Schlechter, C. L., Dhaenens, C.-M., Mohand-Said, S., et al. (2016) · Translational Vision Science & Technology · doi:10.1167/tvst.5.5.10 · Cited by 46 · cited 1×
“Concerning best-corrected visual acuity (BCVA), it was first established with repetitive examinations that for this population, a gain is considered as it when more than eight letters of improvement were recorded [163].”
BackgroundVink, C. A., Counsell, J. R., Perocheau, D. P. B., Karda, R., Buckley, S. M. K., Brugman, M. H., Galla, M., Schambach, A., McKay, T. R., Waddington, S. N., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.028 · Cited by 46 · cited 1×
“proposed to move the ψ and RRE sequences downstream of the SIN 3′LTR in the LTR1 LV [48].”
BackgroundNosov, M., Wilk, M. M., Morcos, M., Cregg, M., O’Flynn, L., Treacy, O., & Ritter, T. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03948.x · Cited by 42 · cited 1×
“Another candidate to reduce inflammation and prolong graft acceptance in allogenic conditions was tested with an LV vector coding for programmed death-ligand 1 (PDL1 [201]).”
MethodCorneal Endothelial Cells Are Protected from Apoptosis by Gene Therapy
Fuchsluger, T. A., Jurkunas, U. V., Kazlauskas, A., & Dana, R. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.079 · Cited by 42 · cited 1×
“To translate such technology to human applications, human cornea explants were challenged with the previously cited vectors (3 × 105 IU/mL, [195]) before apoptosis induction by two chemical compounds, actinomycin and etoposide.”
MethodKachi, S., Binley, K., Yokoi, K., Umeda, N., Akiyama, H., Muramatu, D., Iqball, S., Kan, O., Naylor, S., & Campochiaro, P. A. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.046 · Cited by 41 · cited 1×
“An EIAV vector, the equine analog of LV, was engineered to drive the expression of each of these factors under the control of the VMD2 promoter specific for RPE cells [141].”
BackgroundMeasles Virus Glycoprotein-Based Lentiviral Targeting Vectors That Avoid Neutralizing Antibodies
Kneissl, S., Abel, T., Rasbach, A., Brynza, J., Schneider‐Schaulies, J., & Buchholz, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046667 · Cited by 40 · cited 1×
“Interestingly, point mutations of the native MV glycoprotein also allow decreased neutralization by the human sera of the recombinant MV envelope compared to native MV [128].”
BackgroundMurakami, Y., Ikeda, Y., Yonemitsu, Y., Miyazaki, M., Inoue, M., Hasegawa, M., Sueishi, K., & Ishibashi, T. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.102 · Cited by 40 · cited 24×
“(2010) pseudotyped SIV vectors with a Sendai envelope (SeV-SIV) to optimize gene expression before testing them in two different approaches of gene transfer in the RPE cells to suppress laser photocoagulation-induced CNV [109].”
BackgroundMethodInfluentialMiyazaki, M., Ikeda, Y., Yonemitsu, Y., Goto, Y., Murakami, Y., Yoshida, N., Tabata, T., Hasegawa, M., Tobimatsu, S., Sueishi, K., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.132 · Cited by 39 · cited 1×
“5× 107 TU/mL) and was subretinally injected 2 weeks prior to RGC injury [189].”
MethodVerrier, J. D., Madorsky, I., Coggin, W. E., Geesey, M., Hochman, M., Walling, E., Daroszewski, D., Eccles, K. S., Ludlow, R., & Semple-Rowland, S. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020553 · Cited by 38 · cited 2×
“element, which promotes the translation of a second protein from a unique mRNA [36], or by the 2A element, which mediates the cleavage of two proteins from the same mRNA [37].”
BackgroundDinslage, S., Hueber, A., Diestelhorst, M., & Krieglstein, G. K. (2004) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-003-0835-1 · Cited by 38 · cited 1×
“Pressure reduction (about 35%) is in accordance with chronic treatment using drops of prostaglandin analogs (reduction of 25%, [181]).”
ResultDNA damage enhances integration of HIV-1 into macrophages by overcoming integrase inhibition
Koyama, T., Sun, B., Tokunaga, K., Tatsumi, M., & Ishizaka, Y. (2013) · Retrovirology · doi:10.1186/1742-4690-10-21 · Cited by 38 · cited 5×
“Additionally, the use of integrative-deficient LV (IDLV) can also be an efficient alternative for non-dividing cells [51,52].”
MethodInfluentialMorris, G., & Schorge, S. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.03.010 · Cited by 37
Lentivirus‐mediated gene transfer of interleukin 10 to the ovine and human cornea
Parker, D. G., Coster, D. J., Brereton, H. M., Hart, P. H., Koldej, R. M., Anson, D. S., & Williams, K. A. (2010) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2010.02261.x · Cited by 36 · cited 4×
“Indeed, the use of an adeno-viral vector to transduce the cornea allowed a tremendous production of IL-10, up to more than 103 times those obtained with the LV vector in similar conditions, and prolonged the graft survival by 35 days [200] instead of 7 days with the LV.”
BackgroundInfluentialInsights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons
Caballero, B. R., Sherman, S. J., & Falk, T. (2017) · Parkinson s Disease · doi:10.1155/2017/4263795 · Cited by 36 · cited 1×
“Indeed, VEGF supports the survival of different neurons [132], and the constant inhibition of VEGFA may lead to a loss of vessel fenestration and thinning of the vasculature [133].”
BackgroundIdentification, quantification and age-related changes of human trabecular meshwork stem cells
Sundaresan, Y., Muthukkaruppan, V., Ramasamy, K. S., & Chidambaranathan, G. P. (2019) · Eye and Vision · doi:10.1186/s40662-019-0156-z · Cited by 34
Cornetta, K. G., Duffy, L., Feldman, S. A., Mackall, C. L., Davila, M. L., Curran, K. J., Junghans, R. P., Tang, J. Y., Kochenderfer, J. N., O'Cearbhaill, R. E., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.08.006 · Cited by 32 · cited 1×
“Moreover, no RCLs were identified with the third generation of LV, validating the use of the four plasmid systems for therapeutic purposes [42,47].”
BackgroundProduction of Trans-Lentiviral Vector with Predictable Safety
Kappes, J. C., Wu, X., & Wakefield, J. (2003) · Humana Press eBooks · doi:10.1385/1-59259-304-6:449 · Cited by 31 · cited 3×
“In addition, other systems were developed to minimize RCLs, such as Rev-independent LV [44] or a five plasmids trans-lentiviral system, which separates the RT-IN from the Gag-Pol [45,46].”
MethodTan, J., Liu, G., Zhu, X., Wu, Z., Wang, N., Zhou, L., Zhang, X., Fan, N., & Liu, X. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.021 · Cited by 31 · cited 2×
“The trabecular meshwork was transduced with LV-C3-GFP or LV-GFP vectors [83].”
MethodRetinal Degeneration Progression Changes Lentiviral Vector Cell Targeting in the Retina
Calame, M., Cachafeiro, M., Philippe, S., Schouwey, K., Tekaya, M., Wanner, D., Sarkis, C., Kostic, C., & Arsenijevic, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023782 · Cited by 29 · cited 2×
“The Mokola virus envelope was also used in the retina to strongly target the RPE [106,107] but also Müller cells in degenerating conditions [98].”
BackgroundMethodSelf-citationComisel, R.-M., Kara, B., Fiesser, F. H., & Farid, S. S. (2021) · Biochemical Engineering Journal · doi:10.1016/j.bej.2021.108202 · Cited by 28 · cited 1×
“Even if the establishment of this type of stable cell line requires a certain investment, it appears to be a pertinent approach for the large-scale manufacturing of approved vectors [66].”
BackgroundGuibinga, G.-H., & Friedmann, T. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.002 · Cited by 27 · cited 1×
“Moreover, the fusion of GP64 with a complement decay factor (CD55) allowed it to escape from human and primate serum inactivation [119].”
BackgroundMiskin, J., Chipchase, D., Rohll, J. B., Beard, G. L., Wardell, T. W., Angell-Manning, D., Roehl, H. H., Jolly, D. J., Kingsman, S. M., & Mitrophanous, K. A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302666 · Cited by 26 · cited 1×
“Each corresponding titer was defined by measuring the reverse transcriptase activity (product-enhanced reverse transcriptase (PERT)) and RNA copy number using qRT-PCR [36,78].”
MethodGene Therapy Regenerates Protein Expression in Cone Photoreceptors in Rpe65R91W/R91W Mice
Kostic, C., Crippa, S. V., Pignat, V., Bemelmans, A.-P., Samardzija, M., Grimm, C., Wenzel, A., & Arsenijevic, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016588 · Cited by 26 · cited 1×
“In another mouse model of RPE65 deficiency in which the R91W missense mutation leads to a slow degeneration, gene augmentation was also efficient during the degenerative process [154].”
BackgroundSelf-citationLipinski, D. M., Barnard, A. R., Issa, P. C., Singh, M. S., De Silva, S. R., Trabalza, A., Eleftheriadou, I., Ellison, S. M., Mazarakis, N. D., & MacLaren, R. E. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.009 · Cited by 24 · cited 2×
“Other envelopes, such as the Venezuelan equine encephalitis virus-derived glycoprotein (VEEV-G), also allow RPE transduction but present a higher toxic effect in mice, illustrated by decreased ERG response and ONL thickness with time [100].”
BackgroundAskou, A. L., Benckendorff, J. N. E., Holmgaard, A., Storm, T., Aagaard, L., Bek, T., Mikkelsen, J. G., & Corydon, T. J. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.079 · Cited by 24 · cited 1×
“The efficacy of the vector containing three miRNAs sequences integrated instead of the intron was validated in an in vitro model of endothelial cell tube formation dependent on VEGFA expression [138,139].”
BackgroundViral-vector-delivered anti-angiogenic therapies to the eye
Koponen, S., Kokki, E., Kinnunen, K., & Ylä-Herttuala, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020219 · Cited by 24
Human immunodeficiency viruses: neutralization and receptors.
Weiss, R. A., Clapham, P. R., McClure, M. O., McKeating, J. A., McKnight, Á., Dalgleish, A. G., Sattentau, Q. J., & Weber, J. N. (1988) · PubMed · Cited by 23
Detection of Replication Competent Lentivirus Using a qPCR Assay for VSV-G
Skrdlant, L. M., Armstrong, R. J., Keidaisch, B. M., Lorente, M. F., & DiGiusto, D. L. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.09.001 · Cited by 23
Miyazaki, M., Ikeda, Y., Yonemitsu, Y., Goto, Y., Kohno, R.-I., Murakami, Y., Inoue, M., Ueda, Y., Hasegawa, M., Tobimatsu, S., et al. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1257 · Cited by 22 · cited 3×
“An SIV was used to express hPEDF [79] (10 μL of 2.”
MethodEfficient lentiviral gene transfer into corneal stroma cells using a femtosecond laser
Bemelmans, A., Arsenijévic, Y., & Majo, F. (2009) · Gene Therapy · doi:10.1038/gt.2009.41 · Cited by 22 · cited 1×
“Such an approach was tested in pig cornea explants with an HIV-derived vector expressing GFP (LV-CMV-GFP) and allowed stable GFP expression from 5 to 21 days in culture in four layers of stromal cells on the endothelial side and eight layers on the epithelial side [97].”
MethodLee, E. S., Rasmussen, C. A., Filla, M. S., Slauson, S. R., Kolb, A. W., Peters, D. M. P., Kaufman, P. L., Gabelt, B. T., & Brandt, C. R. (2014) · Current Eye Research · doi:10.3109/02713683.2014.884593 · Cited by 22 · cited 22×
“Glaucoma is characterized by an elevated IOP and the loss of RGC function and survival.”
MethodInfluentialIkeda, Y., Yonemitsu, Y., Miyazaki, M., Kohno, R.-I., Murakami, Y., Murata, T., Tabata, T., Ueda, Y., Ono, F., Suzuki, T., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.009 · Cited by 21 · cited 3×
“The toxicological profile was evaluated as promising with minimal effect on retinal function (measured by electroretinogram (ERG)) and inflammation while presenting a long-term expression [75,81].”
BackgroundMatet, A., Kostic, C., Bemelmans, A.-P., Moulin, A., Rosolen, S. G., Martin, S., Mavilio, F., Amirjanians, V., Stieger, K., Lorenz, B., et al. (2017) · Translational Research · doi:10.1016/j.trsl.2017.06.012 · Cited by 20
Self-citationAhmed, S., Waddington, S. N., Boza-Moran, M.-G., & Yáñez‐Muñoz, R. J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.029 · Cited by 20 · cited 1×
“Additionally, the use of integrative-deficient LV (IDLV) can also be an efficient alternative for non-dividing cells [51,52].”
Corre, G., Seye, A. K., Frin, S., Ferrand, M., Winkler, K., Luc, C., Dorange, F., Rocca, C. J., & Galy, A. H. M. (2022) · Gene Therapy · doi:10.1038/s41434-022-00315-8 · Cited by 19 · cited 1×
“Several approaches to determine both the integration site and the vector copy number per cell have been developed and recently improved, ranging from optimized linear amplification-mediated PCR (LAM-PCR) [25] to enhanced-specificity tagmentation-assisted PCR (esTag-PCR) [26] or digital droplet PCR (ddPCR), associated…”
MethodBalaggan, K. S., Durán, Y., Georgiadis, A., Thaung, C., Barker, S. E., Buch, P. K., MacNeil, A., Robbie, S. J., Bainbridge, J. W., Smith, A. J., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.194 · Cited by 18 · cited 1×
“hrGFP vectors (5 × 108 TU ml−1) did not promote ocular tumor growth in any of the animals tested [28].”
BackgroundGeographic atrophy: where we are now and where we are going
Richard, A. J., Duker, J. S., & Reichel, E. (2021) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000763 · Cited by 18 · cited 1×
“For dry AMD, although several pathways were described to contribute to the disease progression (such as the inflammatory response and lipid homeostasis), no clear actors at the origin of the disease were identified to serve for effective therapeutic development [130].”
BackgroundInsights into HIV uncoating from single-particle imaging techniques
Zhang, M. J., Stear, J. H., Jacques, D. A., & Böcking, T. (2022) · Biophysical Reviews · doi:10.1007/s12551-021-00922-6 · Cited by 18 · cited 3×
“The uncoating of the capsid is still not clear as CA was shown to influence reverse transcription, nuclear import, and provirus integration [11].”
BackgroundInfluentialEffects of Lentivirus-Mediated C3 Expression on Trabecular Meshwork Cells and Intraocular Pressure
Tan, J., Fan, N., Wang, N., Feng, B.-K., Yang, M., Liu, G., Wang, Y., Zhu, X., Kaufman, P. L., Pang, I.-H., et al. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24978 · Cited by 17
Long-Term Decrease of Intraocular Pressure in Rats by Viral Delivery of miR-146a
Luna, C., Parker, M., Challa, P., & González, P. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.8.14 · Cited by 17 · cited 2×
“A similar approach was performed using an LV coding for miR-146a [177], expressed during replicative senescence of human trabecular meshwork cells.”
BackgroundMethodThe Long-Noncoding RNA TUG1 Regulates Oxygen-Induced Retinal Neovascularization in Mice via MiR-299
Wang, Y., Wang, X. B., Wang, Y., Ma, Y., & Di, Y. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.1.37 · Cited by 17 · cited 2×
“To explore the possible role of Tug1 in an ROP mouse model, oxygen-induced retinopathy (OIR) was triggered by exposing PN7 mice to a hyperoxic condition (75% oxygen) for 5 days, followed by a return to a normoxic environment [144].”
BackgroundIkeda, Y., Yonemitsu, Y., Miyazaki, M., Kohno, R.-I., Murakami, Y., Murata, T., Goto, Y., Tabata, T., Ueda, Y., Ono, F., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.048 · Cited by 15 · cited 2×
“The toxicological profile was evaluated as promising with minimal effect on retinal function (measured by electroretinogram (ERG)) and inflammation while presenting a long-term expression [75,81].”
BackgroundRyu, J., Chan, W., Wettengel, J. M., Hanna, C. B., Burwitz, B. J., Hennebold, J. D., & Bimber, B. N. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.009 · Cited by 13 · cited 1×
“Several approaches to determine both the integration site and the vector copy number per cell have been developed and recently improved, ranging from optimized linear amplification-mediated PCR (LAM-PCR) [25] to enhanced-specificity tagmentation-assisted PCR (esTag-PCR) [26] or digital droplet PCR (ddPCR), associated…”
MethodViral Vector Effects on Exoenzyme C3 Transferase–Mediated Actin Disruption and on Outflow Facility
Slauson, S. R., Peters, D. M. P., Schwinn, M. K., Kaufman, P. L., Gabelt, B. T., & Brandt, C. R. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15909 · Cited by 12 · cited 1×
“Similar data were obtained with perfused macaca fascicularis eyes treated with an FIV-C3 vector [173].”
ResultAktaş, Z., Rao, H., Slauson, S. R., Gabelt, B. T., Larsen, I. V., Sheridan, R. T. C., Herrnberger, L., Tamm, E. R., Kaufman, P. L., & Brandt, C. R. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22074 · Cited by 12 · cited 1×
“FIV vector transduction was improved in ex vivo macaca mulatta eye organ culture using a single injection of an MG132 proteasome inhibitor in the perfusion system one hour before the FIV injection [182].”
MethodClinical grade lentiviral vector purification and quality control requirements
Shi, R., Jia, S., Liu, H., & Nie, H. (2022) · Journal of Separation Science · doi:10.1002/jssc.202100937 · Cited by 12
Farley, D. C., McCloskey, L., Thorne, B. A., Tareen, S. U., Nicolai, C. J., Campbell, D. J., Bannister, R., Stewart, H. J., Pearson, L. J., Moyer, B., et al. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.17 · Cited by 11
Cited by
Viral Vector-Based Gene Therapy
Li, X., Le, Y., Zhang, Z., Nian, X., Liu, B., & Yang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097736 · Cited by 200
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
The concept of gene therapy for glaucoma: the dream that has not come true yet
Sulak, R., Liu, X., & Smedowski, A. (2024) · Neural Regeneration Research · doi:10.4103/1673-5374.375319 · Cited by 40
“By affecting the outflow in Schlemm’s canal, it leads to the regulation of aqueous humor outflow (Arsenijevic et al., 2022).”
BackgroundGenome Editing, A Superior Therapy for Inherited Retinal Diseases
Yan, A. L., Du, S. W., & Palczewski, K. (2022) · Vision Research · doi:10.1016/j.visres.2023.108192 · Cited by 40
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics
Ou, L., Setegne, M. T., Elliot, J., Shen, F., & Dassama, L. M. K. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00595 · Cited by 33
Metadata
- Authors
- Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C.
- Affiliations
- Unit Retinal Degeneration and Regeneration, Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, 1004 Lausanne, Switzerland
- Fondation Asile des Aveugles (CH)
- Hôpital Ophtalmique Jules-Gonin (CH)
- Corresponding author
- Kostic, Corinne
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-07-31
- Volume
- 14
- Issue
- 8
- Pages
- 1605
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9414879
- OpenAlex
- W4289203946
- Cited by
- 47
- References
- 208
- Citations by year
- 2026: 6 · 2025: 19 · 2024: 12 · 2023: 8 · 2022: 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, cc-by)
- IRIS (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fondation Asile des Aveugles (.)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- lentiviral vectors, ocular gene therapy, age-related macular degeneration, retinopathy of prematurity, inherited retinal disease, Stargardt disease, Usher syndrome, glaucoma, corneal fibrosis, preclinical and clinical studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.